Search Results
Your search for Staff matches 6663 pages
Showing 851 - 900Potentially Targetable Fusion RNAs May Be More Common in Metastatic Breast Cancer Than Previously Realized
Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-09). Fusion mutations occur when a...
Recipients of 2023 Susan G. Komen Breast Cancer Awards Honored
Susan G. Komen presented its 2023 Breast Cancer Awards to four physician-scientists and one research advocate for their contributions to advancing breast cancer discoveries and improving patient outcomes. The five recipients were recognized at the Susan G. Komen Breast Cancer Awards event in San...
Genetic Characteristics of HER2-Low Advanced Breast Cancers May Guide Treatment Selection
Researchers have revealed significant differences in the genetic characteristics of HER2-low advanced breast cancers, which may lead to the development of novel therapeutics for patients, according to recent findings presented by Kahn et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...
Using Estrogen Levels to Predict Who May Benefit From Preventive Treatment With Anastrozole
Investigators have found that estrogen levels measured through blood tests may be predictive of which individuals at high risk of breast cancer will benefit from aromatase inhibitors, according to a recent study presented by Cuzick et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...
Amy Tiersten, MD, on Metastatic Breast Cancer: A Possible Chemotherapy-Free Front-Line Regimen
Amy Tiersten, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses findings from the ASPIRE trial, which showed the combination of anastrozole, palbociclib, trastuzumab, and pertuzumab in the front-line setting was well tolerated and effective, with a clinical...
Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine
Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated,...
Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy
Almost all postmenopausal patients aged 50 to 69 with stage I hormone receptor–positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease-free 5 years after surgery, according to results from the IDEA clinical trial presented at the 2023 San...
Patients With HR-Positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
Using fertility preservation and/or assisted reproductive technologies (ART) did not adversely impact 3-year cancer recurrence rates among patients with hormone receptor–positive breast cancer who paused endocrine therapy to become pregnant, according to results from the POSITIVE trial presented at ...
Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer
Patients with metastatic breast cancer who took part in a 9-month structured exercise program reported less fatigue and an improved quality of life compared to those who did not participate in the exercise program, according to results from the PREFERABLE-EFFECT trial presented at the 2023 San...
Stephen J. Freedland, MD, on Managing Prostate Cancer in Transgender Women
Stephen J. Freedland, MD, of Cedars-Sinai Medical Center, discusses the incidence of prostate cancer in transgender women. Although the rates of disease appear lower than in cisgender men, Dr. Freedland notes the risk is not as limited as case reports may suggest. He also discusses interpreting PSA ...
Novel Targeted Therapies May Benefit Patients With Metastatic Hormone Receptor–Positive/HER2-Negative Breast Cancer
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor–positive/HER2-negative breast cancer. The data were shared in oral...
Risk Model May Accurately Predict Aromatase Inhibitor Nonadherence
A novel risk model may be effective at using baseline sociodemographic and financial measures to predict the risk of long-term aromatase inhibitor nonadherence among patients with breast cancer, according to new findings presented by Hershman et al at the 2023 San Antonio Breast Cancer Symposium...
Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer
A novel selective biomarker tool (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented by Robbins et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PO3-13-11). Background...
Mark D. Tyson, MD, MPH, on High-Risk Non–Muscle-Invasive Bladder Cancer: A Potential New Treatment
Mark D. Tyson, MD, MPH, of the Mayo Clinic School of Graduate Medical Education, discusses the first results from BOND-003, a phase III study of intravesical cretostimogene grenadenorepvec monotherapy for patients with high-risk non–muscle-invasive bladder cancer that does not respond to Bacillus...
CAR T-Cell Therapy May Be Effective—but Unaffordable—as Second-Line Therapy for Patients With DLBCL
Investigators have found that chimeric antigen receptor (CAR) T-cell therapy may be an effective but unaffordable second-line treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Kelkar et al in the Annals of Internal Medicine....
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...
Neoadjuvant Chemotherapy May Help Some Patients With Breast Cancer Skip Regional Nodal Irradiation
For patients whose breast cancer converted from lymph node–positive to lymph node–negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation did not increase the risk of disease recurrence or death 5 years after surgery, according to results from the NRG...
Samson W. Fine, MD, on Clinical Significance of Atypical Small Acinar and Intraductal Proliferations in the Prostate
Samson W. Fine, MD, of Memorial Sloan Kettering Cancer Center, discusses the evolving spectrum of atypical intraductal proliferations in the prostate, from high-grade prostatic intraepithelial neoplasia to intraductal carcinoma. He describes several clinical challenges, including: assessment and...
Chronic Health Conditions May Be Prevalent Among LGB Adolescent and Young Adult Cancer Survivors
Investigators have found that lesbian, gay, and bisexual (LGB) adolescent and young adult cancer survivors in the United States may be more likely to report chronic health conditions compared with their LGB peers without a cancer diagnosis and heterosexual counterparts with a history of cancer,...
Lung-MAP Trial Demonstrates Potential of Public-Private Partnerships in Advancement of Cancer Therapy
The unique public-private partnership that undergirded the Lung-MAP trial for almost a decade may serve as a model for future clinical research that is more rapid, innovative, and inclusive, according to a recent report published by Herbst et al in Clinical Cancer Research. Background The Lung-MAP...
William J. Catalona, MD, on Genetic Testing in Prostate Cancer: Expert Review
William J. Catalona, MD, of Northwestern University Feinberg School of Medicine, reviews the genetic landscape in prostate cancer, including BRCA2 and ATM, two important mutations for aggressive disease; the clinical implications of germline testing such as guiding screening and disease management, ...
FDA Grants Accelerated Approval to Pirtobrutinib for CLL/SLL
On December 1, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton’s tyrosine...
Black Men With Advanced Prostate Cancer May Be Less Likely to Receive Treatment
Investigators have found that Black men diagnosed with more advanced stages of prostate cancer may be significantly less likely to be prescribed novel hormone therapy compared with men from other racial and ethnic groups, according to a recent study published by Martin et al in JAMA Network Open....
Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors
Researchers have uncovered that the regular consumption of navy beans may help modulate markers linked to obesity and disease and improve the gut microbiome in colorectal cancer survivors, according to a novel study published by Zhang et al in eBioMedicine. Background Obesity, poor diet, and...
Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows
Patients who regularly attend screening mammograms may have a reduced risk of breast cancer mortality, according to recent findings presented by Smith et al at the Radiological Society of North America (RSNA) 2023 Scientific Assembly and Annual Meeting (Abstract R1-SSBR10-4). Background Early...
Toxicities Potentially Linked to Combination Immunotherapy for Mesothelioma
The combination of ipilimumab and nivolumab may result in a higher levels of toxicities in patients with unresectable pleural mesothelioma than was reported in the CheckMate 743 trial, according to a recent study published by McNamee et al in the Journal of Thoracic Oncology. Background Australia...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant, Elizabeth Smyth, MD, a consultant in gastrointestinal oncology at the Oxford University Hospitals NHS Foundation Trust in the United Kingdom, commented on the notable impact in pathologic complete response rates with the addition of checkpoint inhibitors in MATTERHORN and...
Adding Checkpoint Inhibition to Perioperative Chemotherapy Boosts Pathologic Complete Response Rates in Gastric Cancers
The addition of immune checkpoint inhibitors to perioperative chemotherapy for gastric and gastroesophageal junction cancers boosts pathologic complete response rates, but the ultimate impact on clinical outcomes remains unclear, according to interim analyses from two phase III trials presented at...
Expert Point of View: Miriam Koopman, MD, PhD
Abstract discussant Miriam Koopman, MD, PhD, Professor of Medical Oncology at the University Medical Center, Utrecht, the Netherlands, and Vice Chair of the Dutch Colorectal Cancer Group, commented that CodeBreaK 300 showed a high degree of tumor shrinkage and a significant progression-free...
CodeBreaK 300: Sotorasib Plus Panitumumab of Benefit in KRAS-Mutated Metastatic Colorectal Cancer
The combination of sotorasib and panitumumab significantly improved progression-free survival compared with standard treatment in patients with chemotherapy-refractory metastatic colorectal cancer with KRAS G12C mutations, the phase III CodeBreaK 300 trial has shown. The KRAS G12C inhibitor...
Expert Point of View: Laura Locati, MD, PhD
Invited discussant of the LIBRETTO-531 trial, Laura Locati, MD, PhD, Associate Professor of Medical Oncology, Department of Internal Medicine and Therapeutics, University of Pavia and Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Italy, commented: “Selpercatinib is a new...
First-Line Selpercatinib: New Standard of Care for RET-Positive Medullary Thyroid Cancer?
First-line treatment with selpercatinib achieved a statistically significant improvement in progression-free survival and overall response rate vs treatment with cabozantinib or vandetanib in patients with multikinase inhibitor–naive, RET-mutant advanced or metastatic medullary thyroid cancer.1 At...
Expert Point of View: Sarat Chandarlapaty, MD, PhD
Invited discussant of TROPION-Lung01, Sarat Chandarlapaty, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, was cautiously optimistic about this new treatment option. “Dato-DXd [datopotamab deruxtecan] has a benefit over standard-of-care docetaxel in the second-line setting. There...
Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...
Novel AI Model May Predict Nonsmokers at High Risk for Lung Cancer
An artificial intelligence (AI) model may be capable of using routine chest x-ray images to identify nonsmokers who may be at high risk for lung cancer, according to new findings presented by Walia et al at the Radiological Society of North American (RSNA) 2023 Scientific Assembly and Annual...
Ultraprocessed Food May Heighten Risk of Head and Neck Cancer and Esophageal Adenocarcinoma
A higher consumption of ultraprocessed foods may be associated with the development of cancer of the upper–aerodigestive tract such as head and neck cancer and esophageal adenocarcinoma, according to a recent study published by Morales-Berstein et al in the European Journal of Nutrition. The new...
Expert Point of View: Marina C. Garassino, MD
Formal discussant of the ALINA trial Marina C. Garassino, MD, of the University of Chicago, agreed these results are “impressive and practice changing.” However, she said, at this point, more consideration is needed before jettisoning chemotherapy. “I don’t think we should stop giving adjuvant...
ALINA Trial: Anticancer Activity of Alectinib Reported in Earlier-Stage, ALK-Positive NSCLC
Treatment with the anaplastic lymphoma kinase (ALK) inhibitor alectinib significantly reduced the risk of recurrence or death by 76% (P < .0001) in patients with completely resected stage IB to IIIA ALK-positive non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy. This...
FDA Investigating Risk of T-Cell Malignancy Following BCMA- or CD19-Directed Autologous CAR T-Cell Immunotherapies
The U.S. Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor (CAR)-positive lymphoma, in patients who received treatment with B cell maturation antigen (BCMA)- or CD19-directed autologous CAR T-cell immunotherapies. Reports were...
Expert Point of View: Zofia Piotrowska, MD
Zofia Piotrowska, MD, of the Massachusetts General Hospital/Harvard Medical School, Boston, noted that MARIPOSA and MARIPOSA-2 are “two well-designed, randomized phase III trials, each meeting its primary endpoints and representing important advances for patients with EGFR-mutant lung cancer.”...
Amivantamab-Based Regimens Show Anticancer Activity in EGFR-Mutated Advanced NSCLC
Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes with regimens incorporating the bispecific antibody amivantamab-vmjw for patients with advanced non–small...
Expert Point of View: Benjamin Besse, MD, PhD
“In patients with exon 20–mutated non–small cell lung cancer, PAPILLON established a new standard of care with amivantamab-vmjw and chemotherapy,” according to study discussant, Benjamin Besse, MD, PhD, Professor of Medical Oncology at Paris-Saclay University, Orsay, and Head of Clinical Research...
PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset
In the phase III PAPILLON trial, the addition of the bispecific antibody amivantamab-vmjw to chemotherapy resulted in a near doubling in median progression-free survival vs chemotherapy alone in patients with untreated non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR)...
Urban Environmental Exposures and Incidence of Breast Cancer
Investigators have uncovered that North Carolina’s urban counties may have higher overall incidences of breast cancer than its rural counties, especially at early stages at diagnosis, according to a recent study published by Gearhart-Serna et al in Scientific Reports. These findings may serve as a...
Durvalumab May Offer Survival Benefit in Patients With NSCLC and Borderline Performance Status
The immune checkpoint inhibitor durvalumab may be safe and effective at improving overall survival in patients who have advanced or metastatic non–small cell lung cancer (NSCLC) and borderline performance status, according to a recent study published by Shaverdashvili et al in eClinicalMedicine....
Lack of Basic Care in Patients With Colorectal Cancer in Sub-Saharan Africa
A high proportion of patients with colorectal cancer in Sub-Saharan Africa may receive no treatment or inadequate treatment, regardless of the disease’s curability, according to a recent study published by Hämmerl et al in JNCCN–Journal of the National Comprehensive Cancer Network. The new findings ...
FDA Approves Nirogacestat for Desmoid Tumors
On November 27, the U.S. Food and Drug Administration (FDA) approved the selective gamma secretase inhibitor nirogacestat (Ogsiveo) for adult patients with progressing desmoid tumors who require systemic treatment. This is the first approved treatment for desmoid tumors. DeFi Trial Efficacy was...
Expert Point of View: Noemí Reguart, MD, PhD
Abstract discussant Noemí Reguart, MD, PhD, an oncologist at the Hospital Clinic Barcelona, underscored the “impressive” progression-free and overall survival results of the phase III ETER701 trial, which have “never been achieved before in extensive-stage small cell lung cancer.” According to Dr. ...
Phase III Trial Shows Novel Four-Drug Immunotherapy Regimen Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...
Expert Point of View: Upal Basu Roy, PhD, MPH
Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...
